ОбзорГрафикПрофильОсновная статистикаФинансовые показателиНовостиTraderScreen

Biofrontera AG/  DE000A4BGGM7  /

Cboe Europe CXE
-  - Изменение - Объем сделки Бид- Предложение- Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
-EUR - -
Оборот: -		 -Величина цены спроса: - -Величина цены предложения: - 8.37 млнEUR - -
GlobeNewswire 14.08 Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire 24.06 Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
GlobeNewswire 10.11.2023 The Benchmark Company Announces Upcoming 12th Annual Discovery One-on-One Investor Conference
GlobeNewswire 09.10.2023 ROTH MKM to Host Healthcare Opportunities Conference on October 12th at the Yale Club in New York Ci...
GlobeNewswire 17.03.2022 Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of De...
GlobeNewswire 14.03.2022 Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Prote...
GlobeNewswire 09.03.2022 Biofrontera Inc. to Present at the 34th Annual Roth Conference
GlobeNewswire 07.03.2022 Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors
GlobeNewswire 14.02.2022 Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs
GlobeNewswire 01.02.2022 Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBC...
GlobeNewswire 18.01.2022 Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the S...
GlobeNewswire 13.01.2022 Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
GlobeNewswire 10.01.2022 Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
GlobeNewswire 30.12.2021 Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant...
GlobeNewswire 13.12.2021 Biofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz®...
GlobeNewswire 08.12.2021 Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp
GlobeNewswire 06.12.2021 Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with ...
GlobeNewswire 02.12.2021 Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol
GlobeNewswire 02.12.2021 Biofrontera Inc. Announces Closing of $15 Million Private Placement
GlobeNewswire 30.11.2021 Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
GlobeNewswire 29.11.2021 Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules
GlobeNewswire 23.11.2021 Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021
GlobeNewswire 19.11.2021 Biofrontera AG announces mediation results
GlobeNewswire 18.11.2021 The Benchmark Company Announces Its Upcoming 10th Annual One-on-One Discovery Conference
GlobeNewswire 17.11.2021 Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021